Gilead Sciences, Inc. GILD reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.86, which beat the Zacks Consensus Estimate of $1.83. The bottom line was down from $1.90 reported a ...

GILD beats Q1 estimates as HIV and Trodelvy sales rise, but shares slip after the company cuts its 2026 EPS outlook.

Gilead Sciences posted better-than-anticipated earnings for the first quarter. Shares fell anyway.

Add Yahoo as a preferred source to see more of our stories on Google. Adam Castillejo, known as "the London Patient," recovered from cancer and HIV following a stem cell transplant. Sabine Dobel/dpa ...

GSK (GSK) reported better-than-expected financials for Q1 2026 on Wednesday as sales from its HIV and cancer medicines offset a sales decline for its general medicines, including its respiratory ...

Gilead Sciences, Inc. GILD posted better-than-expected third-quarter 2025 results and lifted the lower end of its product sales. Adjusted earnings per share (EPS) of $2.47 beat the Zacks Consensus ...

Joe Biden is seeking to one-up President Trump on the fight against HIV by pledging to end the epidemic by 2025 – an ambitious goal that would beat the current administration's goal by five years, ...